Phase 2 N=42 First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate in Adult CKD-5HD Patients: Cmax. — 207 h*ug/dL
Phase 2 N=80 POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma
Glaucoma
Primary: Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months — -2.3; -6.4 mmHg
Phase 2 N=20 Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
Neuropathic Diabetic Ulcer - Foot
Primary: Number of Participants Experiencing Adverse Events — 20 Participants
Phase 2 N=363 A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
Acne Vulgaris
Primary: Investigator's Global Assessment (IGA) "Success" - Week 12 — 5; 3; 2; 6 Participants
Phase 2 N=60 Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)
Autism Spectrum Disorder
Primary: Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Function — -2.43; -3.06; -1.34; -3.03 units on a scale
Phase 2 N=8 This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
Colitis, Ulcerative
Primary: The Total Number of Deregulated Genes Comparing Baseline to Post Treatment, Analysed by Gene Expression of Mucosal Biopsies Via RNA Sequencing, Per Time Point up to Week…
Phase 2 N=51 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Chronic Neutrophilic Leukemia
Primary: Percentage of First 25 Enrolled Patients With a Hematologic Response to Ruxolitinib (Complete Response (CR), Partial Response (PR)) — 32; 4 percentage of participants…
Phase 2 N=33 Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Lymphoma
Primary: Response to Treatment — 0; 9 participants
Phase 2 N=303 A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 12 — 13.3; 29.5; 42.6; 46.7 percentage of…
Phase 2 N=50 Saracatinib and Alcohol Drinking
Alcohol Drinking
Primary: Change in the Number of Drinks Consumed From Baseline to Day 8 (Minus Baseline) — -1.85; -2.33 drinks
Phase 2 N=42 Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)
Post-operative Excessive Scarring
Primary: Modified Manchester Scar Scale (MMSS) Score — 8; 11.5 score on a scale
Phase 2 N=95 Smoking, Sex Hormones, and Pregnancy
Nicotine Dependence · Contraception
Primary: Change in Smoking Urges — 5.0; 5.5 score on a scale
Phase 2 N=23 Gabapentin for Bipolar & Cannabis Use Disorders
Bipolar I Disorder · Bipolar II Disorder · Cannabis Use Disorder
Primary: Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy — 2.625; 2.696; 2.609; 2.720 Institutional Units — p=0.711
Phase 2 N=177 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline…